174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
The medical device Sector in India suffers from a considerable cost of manufacturing disability.
The company is expecting tremendous growth and a better quarterly performance
Subscribe To Our Newsletter & Stay Updated
